Schneider, M., Korzeniewski, N., Merkle, K., Schuler, J., Grüllich, C., Hadaschik, B., . . . Duensing, S. (2015). The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal: Implications for targeted therapies. Urologic oncology, 33(2), . https://doi.org/10.1016/j.urolonc.2014.06.001
Chicago-Zitierstil (17. Ausg.)Schneider, Meike, Nina Korzeniewski, Konstanze Merkle, Julia Schuler, Carsten Grüllich, Boris Hadaschik, Markus Hohenfellner, und Stefan Duensing. "The Tyrosine Kinase Inhibitor Nilotinib Has Antineoplastic Activity in Prostate Cancer Cells but Up-regulates the ERK Survival Signal: Implications for Targeted Therapies." Urologic Oncology 33, no. 2 (2015). https://doi.org/10.1016/j.urolonc.2014.06.001.
MLA-Zitierstil (9. Ausg.)Schneider, Meike, et al. "The Tyrosine Kinase Inhibitor Nilotinib Has Antineoplastic Activity in Prostate Cancer Cells but Up-regulates the ERK Survival Signal: Implications for Targeted Therapies." Urologic Oncology, vol. 33, no. 2, 2015, https://doi.org/10.1016/j.urolonc.2014.06.001.